Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVR NYSE:CHRO NASDAQ:FNCH NASDAQ:GMDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.68-0.4%$2.69$7.96▼$24.15$13.52M0.6315,685 shs19,056 shsCHROChromocell Therapeutics$1.34+6.3%$6.85$4.50▼$38.00$8.69M3.6347,337 shs194,032 shsFNCHFinch Therapeutics Group$12.47+3.7%$13.05$1.49▼$15.85$20.03M1.212,038 shs253 shsGMDAGamida Cell$0.17$0.03▼$2.51$5.04M0.939.20 million shs23.04 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir-0.37%-5.63%+3.88%-54.03%-84.28%CHROChromocell Therapeutics0.00%0.00%0.00%-89.37%-87.48%FNCHFinch Therapeutics Group+3.66%-0.64%-5.53%-2.12%+646.71%GMDAGamida Cell0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/ACHROChromocell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/ACHROChromocell Therapeutics 0.00N/AN/AN/AFNCHFinch Therapeutics Group 0.00N/AN/AN/AGMDAGamida Cell 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ACHROChromocell TherapeuticsN/AN/AN/AN/A($1.65) per shareN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/A$14.25 per shareN/AGMDAGamida Cell$1.78M0.00N/AN/A($0.02) per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)CHROChromocell Therapeutics-$7.38M-$1.24N/A∞N/AN/AN/A-453.90%N/AFNCHFinch Therapeutics Group-$74.75M-$8.82N/A∞N/AN/A-69.14%-26.92%N/AGMDAGamida Cell-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/ACHROChromocell TherapeuticsN/AN/AN/AN/AN/AFNCHFinch Therapeutics GroupN/AN/AN/AN/AN/AGMDAGamida CellN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78CHROChromocell TherapeuticsN/A0.600.60FNCHFinch Therapeutics GroupN/A3.873.87GMDAGamida Cell213.142.162.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%CHROChromocell Therapeutics77.96%FNCHFinch Therapeutics Group21.77%GMDAGamida Cell50.34%Insider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%CHROChromocell Therapeutics16.40%FNCHFinch Therapeutics Group44.90%GMDAGamida Cell3.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableCHROChromocell Therapeutics46.49 million5.04 millionN/AFNCHFinch Therapeutics Group1901.61 million885,000No DataGMDAGamida Cell143154.05 million143.70 millionOptionableGMDA, FNCH, ALVR, and CHRO HeadlinesRecent News About These CompaniesGMDA to launch massive demolition drive against encroachments in GurugramNovember 7, 2024 | tribuneindia.comTOne week on, Gurgaon roads still riddled with craters, GMDA's claim rings hollowAugust 29, 2024 | timesofindia.indiatimes.comSunChip System from GamidaJuly 20, 2024 | news-medical.netNGamida Cell Announces New Leadership Under Ownership of Highbridge Capital ManagementJune 18, 2024 | businesswire.comGamida Cell files for U.S. bankruptcy as it undergoes restructuringApril 23, 2024 | bizjournals.comTwo Elbit Medical exit dreams punctured in a weekApril 4, 2024 | en.globes.co.ilEGamida Cell gets grant for method of preparing transplantable NK cell fraction for transplantationMarch 29, 2024 | pharmaceutical-technology.comPGoing private last option for Gamida Cell to remain as going concernMarch 28, 2024 | thepharmaletter.comTGamida Cell to delist as Highbridge takes full ownershipMarch 28, 2024 | en.globes.co.ilEQ4 2023 Gamida Cell Ltd Earnings CallMarch 28, 2024 | finance.yahoo.comGamida Cell, Ltd: Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital ManagementMarch 27, 2024 | finanznachrichten.deGamida Cell, Ltd: Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company UpdateMarch 27, 2024 | finanznachrichten.deWhy Gamida Cell Shares Are Falling TodayMarch 27, 2024 | msn.comGMDA Stock Earnings: Gamida Cell Beats EPS, Beats Revenue for Q4 2023March 27, 2024 | investorplace.comWhy Is Gamida Cell (GMDA) Stock Down 82% Today?March 27, 2024 | investorplace.comGamida Cell GAAP EPS of $0.57 beats by $0.72, revenue of $1.78M beats by $0.72MMarch 27, 2024 | msn.comGamida Cell Annual Net Loss Narrows; To Be Taken PrivateMarch 27, 2024 | markets.businessinsider.comGamida Cell starts restructuring process supported by Highbridge Capital, stock downMarch 27, 2024 | msn.comGamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital ManagementMarch 27, 2024 | globenewswire.comGamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company UpdateMarch 27, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGMDA, FNCH, ALVR, and CHRO Company DescriptionsAlloVir NASDAQ:ALVR$2.68 -0.01 (-0.37%) As of 07/31/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Chromocell Therapeutics NYSE:CHRO$1.34 +0.08 (+6.35%) Closing price 07/1/2025Extended Trading$1.34 0.00 (0.00%) As of 07/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.Finch Therapeutics Group NASDAQ:FNCH$12.47 +0.44 (+3.66%) As of 08/1/2025 02:40 PM EasternFinch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.Gamida Cell NASDAQ:GMDAGamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
